secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rubius Therapeutics, Inc. (—)
CIK:        0001709401
Form:       8-K
Filed at:   2023-02-06T23:59:59+00:00
Accession:  0001104659-23-011161
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Rubius receives Nasdaq delisting notice; three directors resign, CEO extends term
--------------------------------------------------------------------------------

- Nasdaq notified Rubius of delisting on Feb 15, 2023 for bid price <$1.00 and public shell status; company to request hearing.
- CEO Dannielle Appelhans extends employment until March 3, 2023 (previously Jan 31); may provide consulting.
- Chief Scientific Officer Laurence Turka stepped down Jan 31, 2023; remains as consultant.
- Three directors (Cuss, Rosenblatt, Schaffert) resigned Jan 31; no disagreement with company.
- Company continues strategic review; no assurance of value realization for stockholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1709401/000110465923011161/0001104659-23-011161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1709401/000110465923011161/tm235566d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-011161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer